Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium…
The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
The hemophilia A treatment landscape has evolved with the acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment. Offering improved treatment outcomes, Hemlibra…
Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in…
Treatment of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and…
Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides and alpha-glucosidase inhibitors continue to…
Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…
Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic…
Immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment…
The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…
Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on…